Your weekly dose of BioTech-startups: Neurent Medical, reMYND, Sproud
Neurent Medical Closes $25M Series B Funding
Neurent Medical, a Galway, Ireland-based company pioneering innovative treatments for chronic inflammatory sino-nasal diseases, closed a $25m Series B financing.
The round was led by new investor LSP, from its LSP HEF-2 fund, and co-led by Atlantic Bridge, investing from its Growth Fund IV.
The company intends to use the funds to expand its clinical and commercial operations as it prepares for U.S. Food and Drug Administration (FDA) clearance and U.S. commercialization of its proprietary NEUROMARK™ Rhinitis Neurolysis Therapy™, an innovative in-office treatment for chronic rhinitis.
Neurent Medical Closes $25M Series B Funding | FinSMEs
Neurent Medical, a Galway, Ireland-based company pioneering innovative treatments for chronic inflammatory sino-nasal diseases, closed a $25m Series B financing
reMYND Raises €12M; Extends Series B to €24M
reMYND NV, a Leuven Belgium-based clinical stage company developing innovative treatments for Alzheimer’s, diabetes and other diseases caused by cellular dysfunction, extended its Series B financing round to €24m.
The second close of €12mi by a consortium of investors including Korys Investments, FPIM, KU Leuven, PMV, and BNP Paribas Fortis Private Equity follows an initial €12m raised in December 2018.
Proceeds from the funding will allow completion of proof-of-concept clinical trials for both the Alzheimer’s and the diabetes programs in 2022. A first-in-human trial of RES19-T for the treatment of Alzheimer’s was initiated in 2020. reMYND expects to announce the launch of a first-in-human trial in diabetes during 2021.
reMYND Raises €12M; Extends Series B to €24M | FinSMEs
reMYND NV, a Leuven Belgium-based clinical stage company developing innovative treatments for Alzheimer’s, diabetes and other diseases caused by cellular dysfunction, extended its Series B financing round to €24m
Vect-Horus Closes €12M Funding
Vect-Horus, a Marseille, France-based biotech company that designs and develops vectors that enable therapeutic molecules or imaging agents to be delivered to key organs, closed its Series D funding.
The first round, held in September 2020, raised €6.7m and a second round in December 2020 added €5.3m from private investors, bringing the total amount raised in these two rounds to €12m.
The company intends to use the funds to pursue its programs, focusing on identifying new vectors, developing theragnostic (therapeutic and diagnostic) agents in a clinical setting and validating its technology for delivering therapeutic antibodies and nucleic acids.
Vect-Horus Closes €12M Funding | FinSMEs
Vect-Horus, a Marseille, France-based biotech company that designs and develops vectors that enable therapeutic molecules or imaging agents to be delivered to key organs, closed its Series D funding
Endo Tools Therapeutics Secures €8M in Series D Funding
Endo Tools Therapeutics (ETT), a Gosselies, Belgium-based developer of advanced endoscopic medical devices for use by gastroenterologists, closed a Series D funding round of €8m ($9.5M).
The round was led by White Fund, supported by new private investors and the existing investors (FPIM-SFPI, Epimède, Chagral Invest and private investors).
The company will use the funds to submit a regulatory marketing submission for its medical devices to the Food and Drug Administration (FDA) in the US for soft tissue approximation, to seek further reimbursement within the EU, and continue R&D efforts into new products and indications, collate evidence on device capabilities, develop a network of centres of excellence and grow and strengthen the organization.
Endo Tools Therapeutics Secures €8M in Series D Funding | FinSMEs
Endo Tools Therapeutics (ETT), a Gosselies, Belgium-based developer of advanced endoscopic medical devices for use by gastroenterologists, closed a Series D funding round of €8m ($9.5M)
Oslo-born startup SafetyWing snags $8 million to expand insurance options for remote teams
SafetyWing, an Norwegian-founded startup that offers health insurance solutions for the growing remote workforce, has raised $8 million in a Series A round led by early Spotify and Klarna investor Creandum with participation from previous investors Rocketship and byFounders.
The founders’ vision is to “replicate the Norwegian social safety net globally,” particularly as remote work becomes the new normal. So SafetyWing has developed a remote health insurance scheme for startups and businesses with distributed teams, covering 175 countries.
Oslo-born startup SafetyWing snags $8 million to expand insurance options for remote teams – Tech.eu
SafetyWing, an Norwegian-founded startup that offers health insurance solutions for the growing remote workforce, has raised $8 million in a Series A round led by early Spotify and Klarna investor […]
Sproud Raises £4.8M in Funding
Sproud, a Malmö, Sweden-based maker of a range of plant-based milks, raised £4.8M in funding.
VGC Partners made the growth investment.
The company intends to use the funds to grow the team, accelerate distribution and brand building activities in its core markets – including the UK, US and Canada, and further develop its plant-based and 100% vegan product offering.
Sproud Raises £4.8M in Funding | FinSMEs
Sproud, a Malmö, Sweden-based maker of a range of plant-based milks, raised £4.8M in funding
Manus Neurodynamica Raises £1.2M in Funding
Manus Neurodynamica Limited, an Edinburgh, Scotland, UK-based medtech company, raised £1.2M in funding.
Investors included the North East Innovation Fund, supported by the European Regional Development Fund and managed by Northstar Ventures, profit with purpose investor SIS Ventures and Old College Capital, the University of Edinburgh’s venture fund.
The company intends to use the funds to launch its digital pen.
